Ignite Creation Date:
2025-12-24 @ 4:32 PM
Ignite Modification Date:
2026-02-06 @ 4:55 AM
Study NCT ID:
NCT02143466
Status:
ACTIVE_NOT_RECRUITING
Last Update Posted:
2025-09-22
First Post:
2014-05-09
Is Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
AZD9291 in Combination With Ascending Doses of Novel Therapeutics
Sponsor:
AstraZeneca
Organization:
Conditions & Keywords Data
Conditions:
Conditions
| Condition Brief | Condition Text | View |
|---|---|---|
| None | Advanced Non Small Cell Lung Cancer | View |
Keywords:
Keywords
| Keyword Brief | Keyword Text | View |
|---|---|---|
| None | Phase I | View |
| None | Safety | View |
| None | Tolerability | View |
| None | Efficacy | View |
| None | Anti-tumour | View |
| None | AZD9291 | View |
| None | AZD6094 | View |
| None | MEDI4736 | View |
| None | Osimertinib | View |
| None | Savolitinib | View |
| None | Selumetinib | View |
| None | Durvalumab | View |
| None | Ascending Doses | View |
| None | Expansion cohorts | View |
| None | EGFR | View |
| None | Advanced Non-Small Cell Lung Cancer | View |
| None | Tyrosine Kinase Inhibitors | View |